Atopic Dermatitis Market Size Exceed $25.00 Billion By 2032 | CAGR: 15.0%

Atopic Dermatitis Market Size Worth $25.00 Billion By 2032 | CAGR: 15.0%

The atopic dermatitis market size is expected to reach USD 25.00 billion by 2032, according to a new study by Polaris Market Research. The report "Atopic Dermatitis Market Size, Trends, Industry Analysis Report, By Drug Type; By Route of Administration; (oral, Injectable, Topical), By Therapy; (Photo Therapy, Directed Therapy), By End-Use; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Atopic dermis typically starts in childhood and can worsen as people mature. Genetic abnormality, environmental exposure, immune system dysfunction, and difficulties with skin permeability are the causes of atopic dermatitis. Seasonal allergies, cold temperatures, and low humidity are typical causes, and the severity of the sickness will define the appropriate course of therapy.

Several different treatment options are available, as there is no known cure for the atopic dermatitis problem. There are presently more innovative eczema medicines being developed than ever, which have expanded treatment options with minor morbidity. This covers medical procedures, including corticosteroids, antibiotics, emollients, and biological therapy.

Atopic dermatitis is a lucrative market and companies are investing in research and development to develop new products to capture the market. An increase in drugs entering late-stage clinical trials with positive results is expected to support revenue growth for large companies in the coming years.

In December 2021, according to LEO Pharma Inc., the US Food and Drug Administration (USFDA) authorized Adbry (tralokinumab-Adam) to treat people 18 years of age and older with atopic dermatitis whose condition is not well controlled.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:

Conversely, allergic reactions to off-label treatments and the expiration of product patents may pose growth challenges to the atopic dermatitis market. There are expected to be several new opportunities that will influence the expansion of the atopic dermatitis market due to the government's increased support for research and development and the quickening pace of technological progress.

Atopic Dermatitis Market Report Highlights

  • The injectable segment dominated the market due to the increased in the use of parenteral drugs via injections.
  • Hospital segment having dominance in atopic dermatitis market over the forecast period because increases the number of atopic dermatitis cases and rise in the price of medication.
  • The largest market in 2022 was North America, which is predicted to continue to rule the US market. In 2022, About 90% of the need for atopic dermatitis treatments in North America was anticipated to come from the United States. For instance, according to data from the Allergy & Asthma Network, over 91% of patients in the United States itch every day, and 15.5% of teenagers with AD express suicidal thoughts, compared to 9.1% of adolescents overall.
  • Some of the major players operating in the global market include Galderma, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Bausch Health, Bayer AG, Encore Dermatology, Inc., AstraZeneca, Sanofi, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Mylan N.V.,

Polaris Market Research has segmented the atopic dermatitis market report based on drug type, route of administration, therapy, end use, and region:

Atopic Dermatitis, by Drug Type Outlook (Revenue - USD Billion, 2019-2032)

  • Anti-Inflammatory agents
  • Antihistamines
  • Immunosuppressant
  • Interleukin Inhibitors
  • Topical Phosphodiesterase (PDE-4)
  • Antiviral Agents
  • Antibiotics

Atopic Dermatitis, by Route of Administration Outlook (Revenue - USD Billion, 2019-2032)

  • Oral
  • Injectable
  • Topical

Atopic Dermatitis, by Therapy Outlook (Revenue - USD Billion, 2019-2032)

  • Photo Therapy
  • Directed Therapy

Atopic Dermatitis, by End Use Outlook (Revenue - USD Billion, 2019-2032)

  • Hospitals
  • Research Lab
  • Clinics

     Atopic Dermatitis, by Geography Outlook (Revenue - USD Billion, 2019-2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa

License and Pricing

Purchase Report Sections

  • Regional analysis
  • Segmentation analysis
  • Industry outlook
  • Competitive landscape
Request for Discount Pricing